CHROMITOPE SODIUM
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Dec 1971
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Chromitope Sodium is an injectable diagnostic radiopharmaceutical approved in 1971 for nuclear medicine imaging procedures. The product is a chromium-51 labeled compound used to visualize and assess organ function and blood flow. It represents a legacy nuclear medicine technology in the diagnostic imaging space.
LOE Approaching
Legacy diagnostic product approaching end-of-life with minimal commercial expansion; small, specialized team focus on maintenance of existing business.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Work on Chromitope Sodium offers limited upside career progression but provides stable, specialized expertise in nuclear medicine diagnostics and legacy product management. Professionals in this role focus on compliance, operational excellence, and niche market maintenance rather than growth-oriented innovation.
Regulatory Affairs SpecialistSupply Chain Manager
Worked on CHROMITOPE SODIUM at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.